PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
3.56%
G&A growth 3-5% suggests rising overhead costs. Howard Marks would investigate if increases are necessary.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-26.91%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-26.91%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
10.26%
Interest expense growth above 10% signals concerning debt expansion. Seth Klarman would demand justification.
-96.48%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-115.63%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Operating income growth above 15% demonstrates exceptional core profitability. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-304.05%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
-304.05%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-288.66%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
0.11%
Share increase 0-2% indicates slight dilution. Howard Marks would investigate necessity.
3.68%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.